Publisher Correction: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's disease.
作者信息
Milà-Alomà Marta, Ashton Nicholas J, Shekari Mahnaz, Salvadó Gemma, Ortiz-Romero Paula, Montoliu-Gaya Laia, Benedet Andrea L, Karikari Thomas K, Lantero-Rodriguez Juan, Vanmechelen Eugeen, Day Theresa A, González-Escalante Armand, Sánchez-Benavides Gonzalo, Minguillon Carolina, Fauria Karine, Molinuevo José Luis, Dage Jeffrey L, Zetterberg Henrik, Gispert Juan Domingo, Suárez-Calvet Marc, Blennow Kaj
机构信息
Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
出版信息
Nat Med. 2022 Sep;28(9):1965. doi: 10.1038/s41591-022-02037-1.
Abstract
摘要
相似文献
1
Publisher Correction: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's disease.
Nat Med. 2022 Sep;28(9):1965. doi: 10.1038/s41591-022-02037-1.
2
Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease.
EBioMedicine. 2022 Feb;76:103836. doi: 10.1016/j.ebiom.2022.103836. Epub 2022 Feb 12.
3
Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231.
Alzheimers Res Ther. 2021 Dec 4;13(1):198. doi: 10.1186/s13195-021-00939-9.
4
Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease.
Brain. 2020 Dec 5;143(11):3234-3241. doi: 10.1093/brain/awaa286.
5
Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes.
JAMA Neurol. 2021 Sep 1;78(9):1108-1117. doi: 10.1001/jamaneurol.2021.2293.
6
P-tau217 in Alzheimer's disease.
Clin Chim Acta. 2022 Jun 1;531:100-111. doi: 10.1016/j.cca.2022.03.018. Epub 2022 Mar 24.
7
Diagnostic and prognostic performance to detect Alzheimer's disease and clinical progression of a novel assay for plasma p-tau217.
Alzheimers Res Ther. 2022 May 14;14(1):67. doi: 10.1186/s13195-022-01005-8.
8
Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials.
Lancet Neurol. 2022 Aug;21(8):726-734. doi: 10.1016/S1474-4422(22)00168-5. Epub 2022 May 25.
9
Differences Between Plasma and Cerebrospinal Fluid p-tau181 and p-tau231 in Early Alzheimer's Disease.
J Alzheimers Dis. 2022;87(3):991-997. doi: 10.3233/JAD-215646.
10
Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects.
Brain. 2021 Oct 22;144(9):2826-2836. doi: 10.1093/brain/awab163.
引用本文的文献
1
Plasma biomarkers for early detection of alzheimer's disease: a cross-sectional study in a Japanese cohort.
Alzheimers Res Ther. 2025 Jun 7;17(1):131. doi: 10.1186/s13195-025-01778-8.
2
Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability.
Nat Aging. 2024 Nov;4(11):1529-1537. doi: 10.1038/s43587-024-00731-y. Epub 2024 Nov 12.
3
Identification of late-stage tau accumulation using plasma phospho-tau217.
EBioMedicine. 2024 Nov;109:105413. doi: 10.1016/j.ebiom.2024.105413. Epub 2024 Nov 4.
4
Nucleic acid aptamer-based electrochemical sensor for the detection of serum P-tau231 and the instant screening test of Alzheimer's disease.
Mikrochim Acta. 2024 May 14;191(6):328. doi: 10.1007/s00604-024-06395-0.
5
CSF p-tau205: a biomarker of tau pathology in Alzheimer's disease.
Acta Neuropathol. 2024 Jan 6;147(1):12. doi: 10.1007/s00401-023-02659-w.
6
The emerging role of blood biomarkers in diagnosis and treatment of Alzheimer's disease.
Eur Geriatr Med. 2023 Oct;14(5):913-917. doi: 10.1007/s41999-023-00847-1.
7
Specific post-translational modifications of soluble tau protein distinguishes Alzheimer's disease and primary tauopathies.
Nat Commun. 2023 Jun 22;14(1):3706. doi: 10.1038/s41467-023-39328-1.
Zotero 插件